<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137722">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720381</url>
  </required_header>
  <id_info>
    <org_study_id>2001078</org_study_id>
    <nct_id>NCT01720381</nct_id>
  </id_info>
  <brief_title>OptiScanner Versus Standard Blood Glucose Monitoring</brief_title>
  <official_title>Manual vs. Automated moNitoring Accuracy of GlucosE II (MANAGE II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OptiScan Biomedical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OptiScan Biomedical Corporation</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to demonstrate the accuracy of the OptiScanner in measuring blood glucose
      levels in critically ill patients when compared to a reference YSI 2300 STAT Plus and the
      Gem 3000, the reference standard for Erasme University Hospital.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Glucose Prediction error</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent (%) predicted error is the percent (%) error result of the OptiScanner on central venous blood from the superior cava versus the YSI and the GEM using arterial blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clarke Error Grid analysis</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Clarke Error Grid analysis shows the percentage of paired values falling within each zone between the glucose results of the OptiScanner on central venous versus the YSI and the GEM  using arterial blood.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hyperglycemia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      One additional blood sample (4 ml)will be collected once a day, separated into Draw an
      additional ~ 4.0 mL from the subject into a syringe once per every 24 hour period. The study
      site will indicate where and at what time the sample was taken.  This sample is placed into
      a sodium heparin tube, labeled with the subject number and sampling time and centrifuged on
      a refrigerated centrifuge. The gained plasma will be frozen at minus 70 degrees Celsius or
      less and may be used for potential analysis by the Sponsor, should an analysis of outliers
      indicate the potential presence of an interferent.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients admitted to the intensive care unit (ICU) of Erasme University
        Hospital in Brussels, Belgium.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed consent.

          -  Age ≥ 18 years.

          -  Admitted to the ICU of Erasme University Hospital.

          -  Expected ICU stay of ≥ 3 days at the time of enrollment (as judged by the Principle
             Investigator).

          -  APACHE II score of ≥ 10, within the first 24 hours of ICU admission.

          -  Existing central venous catheter + arterial catheter.

          -  No participation in any other investigational interventional study while enrolled in
             this study.

          -  Hyperglycemia (BG &gt; 150 mg/dl) at the time of admission.

        Exclusion Criteria:

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles Preiser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Durand, BS</last_name>
      <phone>+32 255 555 44 54</phone>
      <email>ddurand@ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Charles Preiser, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Brasseur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Fagnoul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>monitoring</keyword>
  <keyword>blood glucose</keyword>
  <keyword>intensive care unit</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
